BRAIN and NERVE－神経研究の進歩67巻11号

2015年11月発行

記事購入ページに移動

増大特集 ギラン・バレー症候群のすべて—100年の軌跡

脱髄型ギラン・バレー症候群の標的分子

著者： 森雅裕¹

所属機関： ¹千葉大学大学院医学研究院神経内科学

ページ範囲：P.1359 - P.1369

ギラン・バレー症候群は脱髄型（AIDP）と軸索型（AMAN）に分かれ，後者はガングリオシドが標的分子であることが明らかにされているが，特に欧米で比率の高い脱髄型は長年研究が続けられてきたにもかかわらず，その標的分子が明らかにされてこなかった。近年，ランヴィエ絞輪部周辺の分子に注目が集まり，サイトメガロウイルス関連AIDPではモエシンが標的抗原であることが報告されている。

参考文献

1) Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, et al: An acute axonal form of Guillain-Barré polyneuropathy. Brain 109: 1115-1126, 1986

2) Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl: S21-S24, 1990

3) Kuwabara S, Yuki N: Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 12: 1180-1188, 2013

4) Lim JP, Devaux J, Yuki N: Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun Rev 13: 1070-1078, 2014

5) Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA: Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 46: 245-251, 1993

6) Kwa MS, van Schaik IN, Brand A, Baas F, Vermeulen M: Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol 116: 220-225, 2001

7) Inglis HR, Csurhes PA, McCombe PA: Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry 78: 419-422, 2007

8) Makowska A, Pritchard J, Sanvito L, Gregson N, Peakman M, et al: Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 79: 664-671, 2008

9) Zweiman B, Rostami A, Lisak RP, Moskovitz AR, Pleasure DE: Immune reactions to P2 protein in human inflammatory demyelinative neuropathies. Neurology 33: 234-237, 1983

10) Hughes RA, Gray IA, Gregson NA, Kadlubowski M, Kennedy M, et al: Immune responses to myelin antigens in Guillain-Barré syndrome. J Neuroimmunol 6: 303-312, 1984

11) Da Y, Jia J: Study of antibodies to PMP22, IL-6 and TNF-alpha concentrations in serum in a CMTX1 family. Neurosci Lett 424: 73-77, 2007

12) Devaux JJ, Odaka M, Yuki N: Nodal proteins are target antigens in Guillain-Barré syndrome. J Peripher Nerv Syst 17: 62-71, 2012

13) Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, et al: Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73: 370-380, 2013

14) Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, et al: Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79: 2241-2248, 2012

15) Kawamura N, Yamasaki R, Yonekawa T, Matsushita T, Kusunoki S, et al: Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81: 714-722, 2013

16) Kadlubowski M, Hughes RA: Identification of the neuritogen for experimental allergic neuritis. Nature 277: 140-141, 1979

17) Rosen JL, Brown MJ, Rostami A: Evolution of the cellular response in P2-induced experimental allergic neuritis. Pathobiology 60: 108-112, 1992

18) Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I, et al. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 56: 1227-1229, 2001

19) Willison H, Scherer SS: Ranvier revised: novel nodal antigens stimulate interest in GBS pathogenesis. Neurology 83: 106-108, 2014

20) Lonigro A, Devaux JJ: Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 132: 260-273, 2009

21) Prüss H, Schwab JM, Derst C, Görtzen A, Veh RW: Neurofascin as target of autoantibodies in Guillain-Barré syndrome. Brain 134: e173, 2011

22) Tüzün E, Kinay D, Hacohen Y, Aysal F, Vincent A: Guillain-Barré syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle Nerve 48: 836-837, 2013

23) Rosch RE, Bamford A, Hacohen Y, Wraige E, Vincent A, et al: Guillain-Barré syndrome associated with CASPR2 antibodies: two paediatric cases. J Peripher Nerv Syst 19: 246-249, 2014

24) Iijima M, Tomita M, Morozumi S, Kawagashira Y, Nakamura T, et al: Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73: 1348-1352, 2009

25) Pang SY, Chan KH, Mak WW, Kung MH, Lee CN, et al: Single-nucleotide polymorphism of transient axonal glycoprotein-1 and its correlation with clinical features and prognosis in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 17: 72-75, 2012

26) Sawai S, Satoh M, Mori M, Misawa S, Sogawa K, et al: Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 83: 113-117, 2014

27) Gatto CL, Walker BJ, Lambert S: Local ERM activation and dynamic growth cones at Schwann cell tips implicated in efficient formation of nodes of Ranvier. J Cell Biol 162: 489-498, 2003

28) Kwa MS, van Schaik IN, De Jonge RR, Brand A, Kalaydjieva L, et al: Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 126: 361-375, 2003